- $5M raised in an oversubscribed placement at 4.5c per share – equivalent to 30 day VWAP, and a 33.9% premium to 60 day VWAP.
- Strongly supported by existing domestic institutional investors and sophisticated investors, along with new institutional investors from Australia and the UK.
- Funding provides certainty of capital beyond completion of first-in-human study currently on track to commence in Q4.
- Funding allows IBX to commence preparations for a pivotal study and accelerate R&D in additional indications.
